| Field | Value |
|---|---|
| NCT Number | NCT06402838 |
| Drug | RO7269162 |
| Company | Roche |
| Phase | Phase 2 |
| Status | Recruiting |
| Indication | Alzheimer's Disease |
| Biomarker Focus | Tau PET, CSF tau, plasma tau |
Tau biomarkers have become essential for Alzheimer's disease (AD) diagnosis, disease staging, and therapeutic development. RO7269162 is Roche's tau therapeutic antibody selected for evaluation in this biomarker study. The Phase 2 trial (NCT06402838) focuses on characterizing tau burden and treatment response using multiple biomarker modalities.
Tau pathology correlates more closely with clinical impairment than amyloid pathology in AD[1]. The relationship between tau PET signal and cognitive decline provides critical insights into disease progression and treatment effects.
Tau biomarker modalities:
| Endpoint | Modality | Timepoints |
|---|---|---|
| Tau PET SUVR | PET | Baseline, Week 52 |
| CSF p-tau181 | CSF | Baseline, Week 26, 52 |
| Plasma p-tau181 | Blood | Baseline, Week 26, 52 |
| CSF t-tau | CSF | Baseline, Week 26, 52 |
Tau protein forms neurofibrillary tangles (NFTs) in Alzheimer's disease, composed of hyperphosphorylated tau that has aggregated into paired helical filaments. The distribution of NFTs follows a predictable pattern that correlates with clinical symptoms[2].
Braak staging of tau pathology:
Roche has multiple tau therapeutic candidates:
This biomarker study supports the broader tau development program.
While specific epitopes are proprietary, RO7269162 is designed to:
Anti-tau antibodies may work through multiple mechanisms[@scherer2024]:
Tau PET signal correlates strongly with cognitive impairment:
| Region | Cognitive Domain |
|---|---|
| Entorhinal | Episodic memory |
| Hippocampus | Episodic memory |
| Inferior temporal | Semantic memory |
| Frontal cortex | Executive function |
The AT(N) biomarker framework integrates tau with other AD markers:
| Category | Biomarker | Interpretation |
|---|---|---|
| A (Amyloid) | Amyloid PET, CSF Aβ42 | Amyloid positivity |
| T (Tau) | Tau PET, CSF p-tau | Tau positivity |
| N (Neurodegeneration) | FDG-PET, MRI | Neurodegeneration |
This biomarker study enables:
FDA has expressed interest in biomarker endpoints for AD trials. Tau PET changes may serve as:
| Drug | Company | Mechanism | Stage |
|---|---|---|---|
| E2814 | Eisai | MTBR antibody | Phase 3 |
| Bepranemab | UCB | MTBR antibody | Phase 2 |
| Semorinemab | Roche | N-terminal | Phase 2 (failed) |
| BIIB080 | Biogen | ASO | Phase 2 |
Tau biomarker studies are increasingly important:
Minc, D., et al. Tau PET imaging in Alzheimer's disease: Progress and challenges. Nature Reviews Neurology. 2024. ↩︎
Blennow, K., et al. Cerebrospinal fluid and blood biomarkers for Alzheimer's disease. Lancet Neurology. 2019. ↩︎